Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study

<p><strong>Background:</strong> Ipilimumab has shown long-term overall survival (OS) in patients with advanced melanoma in clinical trials, but robust real-world evidence is lacking. We present long-term outcomes from the IMAGE study (NCT01511913) in patients receiving ipilimumab a...

Full description

Bibliographic Details
Main Authors:	Dalle, S, Mortier, L, Corrie, P, Lotem, M, Board, R, Arance, AM, Meiss, F, Terheyden, P, Gutzmer, R, Buysse, B, Oh, K, Brokaw, J, Le, TK, Mathias, SD, Scotto, J, Lord-Bessen, J, Moshyk, A, Kotapati, S, Wilkinson, J
Format:	Journal article
Language:	English
Published:	BMC 2021

Similar Items

Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
by: Dalle, S, et al.
Published: (2019)

Real‐world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study
by: Middleton, M, et al.
Published: (2016)

Panhypopituitarism induced by ipilimumab
by: Miyu Shiratori, et al.
Published: (2020-01-01)

Ipilimumab: Melanoma and beyond
by: Vishal Patel, et al.
Published: (2011-01-01)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
by: Alexander N Shoushtari, et al.
Published: (2021-10-01)

IPILIMUMAB IN THERAPY OF METASTATIC MELANOMA
by: I. V. SAMOILENKO, et al.
Published: (2016-12-01)

Ipilimumab-Induced Neutropenia in Melanoma
by: Makiko Ban-Hoefen MD, et al.
Published: (2016-08-01)

Ipilimumab induced digital vasculitis
by: Amrita Padda, et al.
Published: (2018-02-01)

Use of ipilimumab in the treatment of melanoma
by: Acharya UH, et al.
Published: (2013-08-01)

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
by: William L Redmond, et al.
Published: (2021-10-01)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
by: Joanne M. Jeter, et al.
Published: (2012-01-01)

Ipilimumab (Immune Checkpoint Inhibitors) Hypophysitis
by: Margot Stagnetto, et al.
Published: (2020-11-01)

IgA Nephropathy Secondary to Ipilimumab Use
by: Sean C. Dougherty, et al.
Published: (2021-11-01)

Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients
by: Constance Reichert, et al.
Published: (2023-08-01)

Adjuvant Ipilimumab in High-Risk Uveal Melanoma
by: Eric Fountain, et al.
Published: (2019-01-01)

Comparisons of therapeutic efficacy and safety of ipilimumab plus GM-CSF versus ipilimumab alone in patients with cancer: a meta-analysis of outcomes
by: Chen P, et al.
Published: (2018-07-01)

Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
by: Priscilla K. Brastianos, et al.
Published: (2021-10-01)

Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma
by: M. N. Khagazheeva, et al.
Published: (2022-06-01)

Urticaria multiforme following nivolumab-ipilimumab therapy
by: Sonal Muzumdar, et al.
Published: (2020-06-01)

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
by: Mary Towner, et al.
Published: (2022-08-01)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
by: Yoshito Nishimura, et al.
Published: (2018-08-01)

Ipilimumab cystic hypophysitis mimicking metastatic melanoma
by: John Wallace, BS, et al.
Published: (2018-06-01)

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients
by: S Ahmad, S, et al.
Published: (2015)

Retinal Toxicity after Initial Administration of Nivolumab and Ipilimumab
by: Adnan Kilani, et al.
Published: (2023-01-01)

Results of combined nivolumab and ipilimumab therapy in patients with cancer
by: M. A. Lyadova, et al.
Published: (2021-12-01)

Toxic Epidermal Necrolysis During Cotherapy with Ipilimumab and Nivolumab
by: Shelby L Kubicki, et al.
Published: (2018-10-01)

Bronchiolitis Obliterans after Combination Immunotherapy with Pembrolizumab and Ipilimumab
by: Amulya Balagani, et al.
Published: (2018-07-01)

Adverse events induced by nivolumab and ipilimumab combination regimens
by: Kohei Somekawa, et al.
Published: (2022-02-01)

CD30+ lymphomatoid skin toxicity secondary to ipilimumab
by: Amelia E. Bush, BS, et al.
Published: (2020-04-01)

Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
by: Wang Wenshi, et al.
Published: (2012-07-01)

Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma
by: Michael P. Chu, et al.
Published: (2020-06-01)

Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab
by: Alexandre Reuben, et al.
Published: (2017-12-01)

Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment
by: Michael R. Cassidy, et al.
Published: (2017-04-01)

Onset of azoospermia in man treated with ipilimumab/nivolumab for BRAF negative metastatic melanoma
by: Matthew J. Rabinowitz, et al.
Published: (2021-01-01)

Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma
by: W. J. Mullally, et al.
Published: (2022-04-01)

A case of ruptured Baker's cyst induced by nivolumab and ipilimumab
by: Marie Kubo, et al.
Published: (2023-06-01)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
by: Nethanel Asher, et al.
Published: (2020-08-01)

Tumor-infiltrating lymphocyte therapy versus ipilimumab in advanced melanoma
by: Shuvadeep Ganguly, et al.
Published: (2023-01-01)

Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma
by: Marco Tucci, et al.
Published: (2018-02-01)

Ipilimumab-Induced Enteritis without Colitis: A New Challenge
by: Marcus Messmer, et al.
Published: (2016-11-01)